| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net earnings | 4,748 | 3,104 | 1,325 | 4,173 |
| Depreciation | 1,064 | 693 | 336 | 998 |
| Amortization of intangible assets | 1,260 | 840 | 420 | 1,413 |
| Share-based compensation | 551 | 431 | 289 | 562 |
| Trade receivables | 874 | 672 | 262 | 533 |
| Inventories | 39 | 252 | 255 | 293 |
| Other, net | 459 | 680 | 436 | 630 |
| Net cash from operating activities | 6,251 | 3,464 | 1,417 | 5,690 |
| Acquisitions of property and equipment | 1,482 | 986 | 484 | 1,487 |
| Acquisitions of businesses and technologies, net of cash acquired | 85 | 30 | - | 0 |
| Proceeds from business dispositions | 0 | 0 | - | 1 |
| Sales (purchases) of other investment securities, net | -46 | 44 | -8 | -9 |
| Other | -12 | -8 | -6 | -5 |
| Net cash from (used in) investing activities | -1,509 | -1,052 | -470 | -1,472 |
| Net borrowings (repayments) of short-term debt and other | -44 | -52 | -36 | -126 |
| Proceeds from issuance of long-term debt | 3 | 3 | 1 | 222 |
| Repayments of long-term debt | 1,503 | 1,002 | 1,001 | 20 |
| Purchases of common shares | 591 | 286 | 280 | 980 |
| Proceeds from stock options exercised | 391 | 322 | 287 | 239 |
| Dividends paid | 3,086 | 2,055 | 1,026 | 2,878 |
| Other | -82 | -82 | - | - |
| Net cash from (used in) financing activities | -4,912 | -3,152 | -2,055 | -3,543 |
| Effect of exchange rate changes on cash and cash equivalents | 65 | 75 | 24 | -13 |
| Net increase (decrease) in cash and cash equivalents | -105 | -665 | -1,084 | 662 |
| Cash and cash equivalents at beginning of period | 7,616 | 7,616 | 7,616 | 6,896 |
| Cash and cash equivalents at end of period | 7,511 | 6,951 | 6,532 | 7,558 |
ABBOTT LABORATORIES (ABT)
ABBOTT LABORATORIES (ABT)